TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* locally advanced (≥T3) resectable rectal adenocarcinoma between 2 and 10 cm from the anal verge.~Exclusion Criteria:~* synchonous metastatis~* previous malignant tumour~* previous radiotherapy/ chemotherapy~* performance status WHO\>2~* contraindication to 5 FU

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: My Dose Coach Mobile App to Support Insulin Titration and Maintenance

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Intervention Group~* Patient receiving care at a UPMC Diabetes Outpatient and/or Inpatient settings~* Adult male and female patients 18 to 75 years old~* HbA1c \> 7.5%~* Recommended to start self titration of basal insulin~* Access to and able to use an iOS (Apple phone operating system) or Android enabled device and have reliable internet access~* Willing and able to use the MDC app~* Able to comprehend basic diabetes survival skills, signs and symptoms of hypoglycemia and treatment of BG~Usual Care Group~* Adult male and female patients 18 to 75 years old~* HbA1c \> 7.5%~* Started on basal insulin in a UPMC Diabetes Outpatient facility within the past three years of study start~* Has blood glucose data available in electronic medical records (EMR) (At least two HbA1c measurements corresponding to baseline and a subsequent time point after insulin titration)~Exclusion Criteria:~* Pregnant or breastfeeding~* Patients unwilling to use MDC app

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- My Dose Coach (Insulin Dosing Support App) (Type: EXPERIMENTAL): Phase 1 Titration: Patients receive insulin therapy education from diabetes educator (DE). Plus, DE trains patients to use My Dose Coach (MDC) for titration guidance according to an algorithm prepared by endocrinology provider (EP). Patients are asked to return for a 3-month (mo) follow-up clinic visit. Patients who successfully reach glycemic target are invited to Phase 2. Other patients are invited to continue titrating for another 3 months.~Phase 2 Maintenance: At 3-mo clinic visit, an EP or DE trains patients the MDC Maintenance Module to support proper insulin dosing. Patients are asked to return for follow-up clinic visits at mo 6.~Patients are surveyed (0, 3, 6 mo) to assess changes in behavioral and psychosocial factors that influence diabetes self-management and MDC acceptability.
- Usual Care Group (Type: ACTIVE_COMPARATOR): A retrospective comparative group will be selected from eligible patients who previously were treated at the University of Pittsburgh Medical Center (UPMC) Diabetes Outpatient Clinics following standard insulin therapy education. Patients in the usual care group will be identified using data available in the electronic medical record system. Propensity score matching will be used to pair intervention and usual care participants during phase 1 of the study (baseline to 3 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lacosamide IV and EEG/EKG (LIVE) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is informed and given ample time and opportunity to think about her/his participation and has given her/his written informed consent.~2. Adult patients 18-65 years~3. Diagnosis of focal epilepsy~4. Continuous EEG and video monitoring~5. Continuous EKG~6. Active EEG showing frequent spikes, electrographic or clinical seizures~Exclusion Criteria:~1. Subject has no IV access.~2. Subject is hemodynamically unstable.~3. Previous use of Lacosamide~4. Primary generalized epilepsy~5. Non-epileptic seizures~6. No significant cardiac, renal or hepatic disease~7. No cardiac arrhythmias including heart block~8. Subject is a pregnant or lactating woman.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 100 mg IV (Type: OTHER): 100 mg IV lacosamide infused over 30 minutes
- 200 mg IV (Type: OTHER): 200 mg IV lacosamide infused over 30 minutes
- 400 mg IV (Type: OTHER): 400 mg IV lacosamide infused over 30 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinical diagnosis of moderate to severe facial rosacea as determined by:~   * At least 8 but no more than 50 total papules and/or pustules (inflammatory lesions)~  * Presence of moderate to severe erythema~  * Presence of telangiectasia.~  * An Overall Rosacea Severity score ≥2.5~2. Patient is male or female over 18 years of age.~3. No known medical conditions that, in the Investigator's opinion could interfere with study participation~4. Patient is willing and able to comply with all requirement of the protocol~5. Patient is willing and able to give written informed consent prior to participation in the study~Exclusion Criteria:~1. Presence of skin diseases at or near the investigational area~2. Immunosuppressed state or other serious systemic disease~3. Signs and/or symptoms of systemic infection~4. Concomitant medication:~   * Use of oral and/or topical antibiotic treatment within 14 days prior to study entry.~  * Use of any topical anti-rosacea agent except antibiotics within 14 days prior to study entry.~  * Use of cyproterone acetate, CPA-containing contraceptives (e.g. Diane) or other corticosteroids (during the last 3 months);~  * Use of retinoids (during the last 4 weeks)~5. Use of artificial sun bath or having a sun holiday during the last 2 weeks~6. Alcohol or drug abuse, according to assessment by the investigator~7. Known or suspected hypersensitivity to Minocycline or any of the excipients in the Study Medication~8. Use of another investigational drug within 30 days prior to entry into this study~9. Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Topical Minocycline Foam FXFM244 Placebo (Type: PLACEBO_COMPARATOR): Minocycline Foam FXFM244 Placebo
- Topical Minocycline Foam FXFM244, 1% (Type: EXPERIMENTAL): Minocycline Foam FXFM244, 1%
- Topical Minocycline Foam FXFM244, 4% (Type: EXPERIMENTAL): Minocycline Foam FXFM244, 4%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~In- and outpatients suffering from CLL, who are treated with Mab Campath, and are routinely monitored with PCR (Polymerase Chain Reaction) for CMV infection during MabCampath treatment and for at least 2 months following completion of treatment.~Exclusion Criteria:~In accordance with Summaries of Product Characteristics (SPC).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alexa, What is Eliquis and Xarelto?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (Patients):~* 18 years of age or older~* Have been prescribed either apixaban or rivaroxaban during their inpatient stay~* Consent to participating in the study~Inclusion Criteria (Nurses):~* Providing direct patient care in select general medicine and orthopedic surgical units~* Consent to participating in the study~Exclusion Criteria:~* Patients will be excluded if they have documented altered mental status, do not speak English, or are being prescribed rivaroxaban or apixaban on discharge only.~* Nurses will be excluded if not providing direct patient care in select general medicine and orthopedic surgical units~* Nurses declining participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: NO_INTERVENTION): Patient's will receive standard education on Xarelto and Eliquis per usual process without use of Alexa based voice recording.
- Alexa Education (Type: ACTIVE_COMPARATOR): Patient's will opt in to receive initial education via Alexa based voice recording on Xarelto and Eliquis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults age 18 years and older who have a confirmed biopsy diagnosis of FSGS.~2. Estimated glomerular filtration rate (eGFR) greater than or equal to 45 ml/min/1.73 m2. If eGFR is 30 - 45 ml/min/1.73 m2, a recent biopsy (within 12 months prior to Screening) must demonstrate \< 50% tubulointerstitial fibrosis.~3. Urine protein:creatinine ratio (UPCR) greater than 1.5 g/g at screening.~4. Treated with at least one but not more than 3 classes of immunosuppressants either alone or in combination, or has a contraindication to use of an immunosuppressant or is intolerant to an immunosuppressant per investigator judgment.~Exclusion Criteria:~1. Diagnosis of collapsing FSGS.~2. Advanced chronic changes on renal biopsy as evidenced by greater than 50% tubulointerstitial fibrosis.~3. Organ transplant.~4. History of malignancy, with the exception of basal or squamous cell carcinoma that has been treated and fully resolved for a minimum of 5 years.~5. Body mass index (BMI) greater than 45 kg/m2.~6. Subjects with a history of prior treatment with or use of interferon, lithium, pamidronate, mTOR inhibitors (eg, sirolimus), testosterone/anabolic steroids, anthracycline (eg, doxorubicin), heroin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06730512 Cohort 1 (Type: EXPERIMENTAL): Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
- PF-06730512 Cohort 2 (Type: EXPERIMENTAL): Subjects in cohort 2 will receive dose 2 IV infusion.
- PF-06730512 Cohort 3 (optional) (Type: EXPERIMENTAL): Subjects in cohort 3 will receive dose 3 IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Neutrophil Extracellular Trap Formation in Newborn Infants at Risk for Inflammatory Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤ 1500 grams or \<30 weeks gestational age at birth~2. Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery~3. Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life.~Exclusion Criteria:~* No other exclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: t

Study Arms:
- Prematurely born infants in the NICU (Type: None): Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤1500 grams or \<30 weeks gestational age at birth
- Healthy term infants (Type: None): Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery
- Infants having surgery at <1 year old (Type: None): Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent, including authorization to release health information~* Skeletally mature, male or female patients 18 to 65 years of age with diagnosis of plantar fasciitis~* Persistent heel pain for more than three months~* Women of child bearing potential must have a negative urine pregnancy test (UPT) at Screening Visit and must use an effective method of birth control during the course of the study~Exclusion Criteria:~* Previous surgery on the midfoot or hindfoot~* Neuromuscular disease~* Systemic muscle weakness~* Planning a pregnancy during the study~* Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to first visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DAXI 240 U (Type: EXPERIMENTAL): DaxibotulinumtoxinA for injection for the treatment of plantar fasciitis (PF) with 240 U
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Positive antigen or PCR test for Lassa fever~* Aged 10 years or above~Exclusion Criteria:~* Patients for end of life care only

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lassa fever (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Normal Aging on Language Processing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age of 30 years and above~* Right handed~* French native speakers~* Affiliation to French social security (Sécurité Sociale)~* Medical interview~* Consent form signed~Exclusion Criteria:~* Cerebral or respiratory pathologies~* Any MRI contrindication

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy adults (Type: None): 20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Circulating Endothelial Cells and Microparticles in Youth

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 8-17 years old~* Currently scheduled for elective bariatric surgery~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Competent adult English speaking subjects~* With limited stage SCLC who have completed standard of care treatment who are responders with no evidence of disseminated disease other than CNS metastasis,~* With recurrent disseminated SCLC after standard of care treatment with symptoms related to central tumor obstruction,~* With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously treated with intratumoral cisplatin~Exclusion Criteria:~* Subjects who do not meet the inclusion criteria~* Subjects who, in the opinion of the investigator, are at risk undergoing a bronchoscopy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- patients with limited stage SCLC (Type: EXPERIMENTAL): Subjects with limited stage SCLC treated sequentially with cisplatin.
- Historical Controls (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Comprehensive Molecular Tests on Antimicrobial Stewardship in Community-acquired Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (18 years of age or older), of both sexes, hospitalized with a diagnosis of CAP in the first 24 hours of the admission.~* Patient or his legal representative gives the informed consent~Exclusion Criteria:~* Patient with acute infection by SARS-CoV-2 being this defined as:~  * Clinic of COVID-19 compatible, PCR positive for SARS-CoV-2 and negative serology for SARS-CoV-2.~OR~* COVID-19 clinic compatible, PCR positive for SARS-CoV-2 (in the last 60 days) and positive serology for SARS-CoV-2.~  * Pregnancy and / or nursing.~ * Severe immunocompromised patients (chemotherapy or radiotherapy in the previous 90 days, use of immunosuppressive drugs, chronic use of corticosteroids at a minimum dose of 15 mg / day in the last two weeks, transplantation of hematopoietic progenitors, solid organ transplant, patients with HIV and CD4 count ≤ 200 cells / mm3).~ * Imminent death (life expectancy ≤ 24 hours).~ * Participation in another clinical trial of pharmacological treatment during the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard diagnostic tests (Type: ACTIVE_COMPARATOR): Patients who will undergo only the standard diagnostic procedures
- Experimental + standard diagnostic tests (Type: EXPERIMENTAL): Patients will undergo described standard diagnostic procedures and in addition, real-time multiplex Protein Chain Reaction (PCR, FilmArray Pneumonia panel Plus ™, Biofire, BioMérieux).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy